Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06654804 · ClinicalTrials.gov registry record · Phase 4

Contrast-enhanced Ultrasound in the Treatment of Acute Spinal Cord Injury

A Phase 4 study of Acute Spinal Cord Injury, sponsored by University of Washington.

Recruiting
Registry status
Phase 4
Development phase
50
Enrollment target
1
Study location

NCT06654804: Recruiting Phase 4 study of Acute Spinal Cord Injury, sponsored by University of Washington.

NCT06654804 is a Phase 4 study of Acute Spinal Cord Injury that is actively recruiting participants, run by University of Washington. The registered enrollment target is 50 participants, above the 35-participant average among 8 other Acute Spinal Cord Injury trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06654804, a Phase 4 study of Acute Spinal Cord Injury, is actively recruiting participants, sponsored by University of Washington.

RECRUITING
Registry status
Phase 4
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Patients with traumatic spinal cord injury (tSCI) often suffer from spinal cord swelling inside the thecal sac, which contains the spinal cord and surrounding fluid, leading to increased pressure on the spinal cord tissue and decreased spinal cord blood flow at the site of injury. The combination of increased pressure and decreased blood flow causes vascular hypoperfusion of the spinal cord and exacerbates the severity of injury. This is also referred to as secondary injury. Thus, knowledge of spinal cord hypoperfusion would allow the treating physician to optimize the hemodynamic condition of the patient with acute spinal cord injury and potentially improve functional outcomes.

Primary Outcome

Knowledge of spinal cord hypoperfusion will allow the physician to optimize the hemodynamic condition of acute spinal cord injury and potentially improve outcomes. The investigators plan to use contrast-enhanced ultrasound to determine decreased blood flow in the spinal cord at the site of injury, during the routine surgery that these patients require to decompress and stabilize their injured spine.

Conditions Studied

Interventions

  • DRUG Perflutren lipid

Study Locations (1)

Washington

  • University of Washington Harborview Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-09-28
Est. Completion 2027-09-15
Phase Phase 4
University of Washington

1,048 total trials

What NCT06654804 shows while recruiting

NCT06654804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, above the 35-participant average among 8 other Acute Spinal Cord Injury trials with a reported enrollment target (43% higher).

The record links to 1 condition, with Acute Spinal Cord Injury appearing as the primary indexed condition, and to 1 intervention - of which Perflutren lipid is the first listed.

NCT06654804 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT06654804 about?

NCT06654804 is a clinical study titled "Contrast-enhanced Ultrasound in the Treatment of Acute Spinal Cord Injury". Patients with traumatic spinal cord injury (tSCI) often suffer from spinal cord swelling inside the thecal sac, which contains the spinal cord and surrounding fluid, leading to increased pressure on the spinal cord tissue and decreased spinal cord blood flow at the site of injury. The combination of...

What is the current status of trial NCT06654804?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-09-28. Estimated completion is 2027-09-15.

What conditions does trial NCT06654804 study?

This clinical trial studies the following conditions: Acute Spinal Cord Injury.

What interventions are being tested in trial NCT06654804?

The interventions under investigation include: Perflutren lipid (DRUG).

Who is sponsoring clinical trial NCT06654804?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06654804 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Spinal Cord Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06654804's enrollment target sits among peer trials

50 2nd of 8 higher than 4 of 8 other Acute Spinal Cord Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Spinal Cord Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06654804, the US trial registry maintained by the National Library of Medicine. NCT06654804 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.